Saturday 17 October 2026 Export PRPH’s income statement to Excel — free account

ProPhase Labs, Inc.

In the quarter to June 2026, revenue fell 18.9%, EPS grew 80.0%, free cash flow grew 56.7% and total debt rose 19.4%, each against the same quarter a year earlier.

0.01 0.00 0.00%

Follow PRPH

Alert me

Market cap: $1.2M
P/E: 0.0×
Fwd P/E: −0.6×
Dividend yield: —
F-score: 4/9
Altman Z: −3.59
Beneish M: −4.90
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 60.12%

Capital & Financial Ratios $m

Market Cap 1.17

Revenue 3.16

Net Income (22.46)

Free Cash Flow (5.53)

Net Debt 5.65

Current Ratio 0.05

Debt/Equity (1.82)

P/E ratio 0.00

Fwd P/E (0.63)

P/S ratio 0.04

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 78.54%

Next Y EPS Growth 55.91%

Next Y revenue growth 859.49%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.90%

10-year low 10-year high

EV/Sales against its own 10 years 38.88%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	0.00	3.00 3.00
2021	0.00	3.00
2020	Powerpack
2019	0.00	2.50 2.50
2018	0.00	1.00 10.00
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	5	1	0	0
Receivables	36	20	2	2
Inventory	2	1	0	0
Other	3	6	—	—
	48	31	3	3

	2023	2024	2025	Q'26
Payables	9	14	41	43
ST’ Debt	—	3	5	6
Other	3	2	3	3
	21	32	53	58

Compound Annual Growth %

	10y	5y	3y
Sales	5.61%	(21.43%)	(67.16%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(8.82%)	(19.77%)	(61.94%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	1	—	—	—
’25	1	1	1	1	4
’24	2	2	1	1	7
’23	19	13	8	—	35
’22	48	29	24	22	123
’21	15	9	9	45	79
’20	2	4	4	5	15

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(3)	0	(3)	(1)	(8)
’24	(5)	(5)	(4)	(4)	(18)
’23	0	(7)	(5)	(1)	(12)
’22	20	5	3	1	29
’21	(8)	4	(6)	(5)	(14)
’20	0	4	0	(7)	(3)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	0	—	—	—
’25	(3)	0	(3)	(1)	(8)
’24	(6)	(5)	(4)	(4)	(18)
’23	(3)	(8)	(5)	2	(14)
’22	19	4	2	(1)	25
’21	(12)	4	(15)	(5)	(27)
’20	0	4	(1)	(6)	(2)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.43)	(0.22)	—	—	—
’25	1.10	(1.10)	(1.60)	(0.14)	(1.74)
’24	(0.70)	(3.30)	(3.50)	(16.33)	(26.10)
’23	0.30	(2.00)	(3.00)	(5.10)	(9.80)
’22	6.80	4.00	0.48	(1.11)	10.20
’21	0.60	(0.90)	(2.60)	6.80	4.00
’20	(0.70)	0.06	(0.40)	(0.84)	(1.80)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	10.80	17.80	21.90	16.30	12.00	44.10	62.00	40.50	6.10	0.41	Analyst estimates 2026–2028 Powerpack
	High	22.40	24.50	66.40	40.00	118.20	160.40	152.50	99.40	74.80	9.30
People
People	Employees	53	46	50	50	95	129	129	113	96	19
	Revenue/emp, $m	0.08	0.21	0.26	0.20	0.15	0.61	0.95	0.31	0.07	0.23
Income, $m
Income, $m	Revenue	4	10	13	10	15	79	123	35	7	4
	Gross margin, %	23.70	19.74	36.42	26.48	31.73	53.12	57.61	44.47	(2.22)	31.85
	EBT	(4)	(4)	(1)	(3)	(2)	5	23	(22)	(42)	(23)
	EBT margin, %	(95.24)	(37.12)	(11.18)	(31.45)	(15.94)	6.71	18.68	(64.02)	(625.26)	(538.25)
	Net income	(3)	41	(2)	(3)	(2)	6	18	(17)	(53)	(15)
	Depreciation	0	0	0	0	0	4	5	7	8	10
Per share, $
Per share, $	Revenue	2.46	6.34	11.52	8.54	12.52	52.10	77.40	20.33	3.39	0.51
	Earnings	(1.70)	26.90	(1.50)	(2.70)	(1.80)	4.10	11.70	(9.80)	(26.10)	(1.74)
	Cash flow	(0.28)	(1.82)	(1.86)	(0.73)	(2.24)	(8.98)	18.02	(6.91)	(8.77)	(0.98)
	Capex	(0.38)	(0.13)	(0.12)	(0.20)	0.34	(8.76)	(2.19)	(1.18)	(0.34)	0.01
	Free cash flow	(0.66)	(1.96)	(1.98)	(0.92)	(1.90)	(17.74)	15.83	(8.09)	(9.11)	(0.97)
	Book value	3.49	20.46	14.48	9.71	9.10	38.64	40.16	28.70	3.68	0.41
	Shares, m	2	2	1	1	1	2	2	2	2	8
Valuation, ×
Valuation, ×	P/E	0.00	0.85	0.00	0.00	0.00	17.93	7.98	0.00	0.00	0.00
	P/S	8.24	3.53	2.73	2.31	7.33	1.38	1.24	2.28	2.25	0.88
	P/B	5.82	1.09	2.18	2.03	10.08	1.86	2.38	1.62	2.07	1.09
	EV/Sales	8.84	1.61	2.33	2.47	7.46	1.29	1.12	2.55	4.72	2.19
	EV/FCF	(33.12)	(5.22)	(0.71)	(22.81)	(49.23)	(3.79)	5.46	(6.41)	(1.76)	(1.16)
Cash, $m
Cash, $m	Operating cash flow	0	(3)	(2)	(1)	(3)	(14)	29	(12)	(18)	(8)
	Capex	(1)	0	0	0	0	(13)	(3)	(2)	(1)	0
	Free cash flow	(1)	(3)	(2)	(1)	(2)	(27)	25	(14)	(18)	(8)
Balance, $m
Balance, $m	Working capital	3	27	14	9	10	46	45	27	(1)	(50)
	Total debt	1	—	—	—	10	11	3	11	17	6
	Net debt	1	(22)	(8)	(1)	2	(7)	(15)	7	17	6
	Shareholders’ equity	6	32	17	11	11	59	64	49	7	4
Returns, %
Returns, %	ROA	(20.76)	174.72	(6.40)	(19.06)	(9.73)	10.39	20.87	(18.69)	(68.80)	(23.96)
	ROIC	(33.82)	(25.17)	(12.36)	(20.51)	(10.47)	11.82	30.16	(23.65)	(100.08)	(122.44)
	ROE	(38.78)	214.71	(7.20)	(22.69)	(19.51)	18.13	30.20	(29.70)	(188.11)	(271.49)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NDRA ENDRA Life Sciences Inc.	$7.7M	— (loss-making)	— (loss-making)	−98.80% (below 0%: shrinking)	n/m	+15.04% (above 0%: growing)	0.00%	0.00%	Compare
XWEL XWELL, Inc.	$7.5M	— (loss-making)	— (loss-making)	−7.08% (below 0%: shrinking)	n/m	−43.02% (below 0%: shrinking)	41.26%	(29.45%)	Compare
TTOO T2 Biosystems, Inc.	$6.5M	— (loss-making)	— (loss-making)	+34.85% (above 0%: growing)	n/m	+53.36% (above 0%: growing)	(106.60%)	(511.89%)	Compare
BIAF bioAffinity Technologies, Inc.	$5.1M	— (loss-making)	— (loss-making)	+18.99% (above 0%: growing)	n/m	−23.69% (below 0%: shrinking)	27.98%	(220.77%)	Compare
DMTKQ DermTech, Inc.	$3.3M	— (loss-making)	— (loss-making)	+10.58% (above 0%: growing)	n/m	+24.87% (above 0%: growing)	18.54%	(533.37%)	Compare
NOTVQ Inotiv, Inc.	$2.8M	— (loss-making)	— (loss-making)	−5.37% (below 0%: shrinking)	n/m	+82.66% (above 0%: growing)	20.95%	(16.41%)	Compare
ISPC iSpecimen Inc.	$2.6M	— (loss-making)	— (loss-making)	−78.70% (below 0%: shrinking)	n/m	−257.73% (below 0%: shrinking)	45.23%	(897.30%)	Compare
AWHL Aspira Women's Health Inc.	$2.4M	— (loss-making)	— (loss-making)	−14.89% (below 0%: shrinking)	n/m	−24.57% (below 0%: shrinking)	55.28%	(89.69%)	Compare
PRPH ProPhase Labs, Inc.	$1.2M	— (loss-making)	— (loss-making)	−18.93% (below 0%: shrinking)	n/m	+56.67% (above 0%: growing)	22.35%	(261.62%)
Median of peers	$4.2M	—	—	−6.22%	—	−4.32%	24.46%	(155.23%)

All 52 Diagnostics & Research stocks →

ProPhase Labs, Inc. (PRPH) key facts

ProPhase Labs, Inc. (PRPH) is a Diagnostics & Research company in the Healthcare sector.
As of October 16, 2026, PRPH traded at $0.01, a market capitalization of $1.2 million.
Return on equity was −271.5% and debt-to-equity -1.82.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −3.59 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.